Dana Investment Advisors Inc. Sells 26,409 Shares of Phibro Animal Health Corporation $PAHC

Dana Investment Advisors Inc. lessened its position in Phibro Animal Health Corporation (NASDAQ:PAHC) by 7.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 328,676 shares of the company’s stock after selling 26,409 shares during the period. Dana Investment Advisors Inc.’s holdings in Phibro Animal Health were worth $12,279,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. 1620 Investment Advisors Inc. grew its holdings in Phibro Animal Health by 77.4% in the 4th quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock worth $25,000 after acquiring an additional 295 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in Phibro Animal Health by 113.2% in the 4th quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock worth $27,000 after acquiring an additional 386 shares during the last quarter. Hughes Financial Services LLC bought a new stake in Phibro Animal Health in the 3rd quarter worth $40,000. iSAM Funds UK Ltd bought a new stake in Phibro Animal Health in the 3rd quarter worth $61,000. Finally, Advisory Services Network LLC bought a new stake in Phibro Animal Health in the 3rd quarter worth $96,000. Institutional investors own 99.34% of the company’s stock.

Insider Buying and Selling at Phibro Animal Health

In other news, CEO Jack Bendheim sold 4,528 shares of Phibro Animal Health stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $48.49, for a total transaction of $219,562.72. Following the sale, the chief executive officer owned 56,152 shares of the company’s stock, valued at approximately $2,722,810.48. The trade was a 7.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 103,088 shares of company stock worth $5,481,030. Insiders own 50.13% of the company’s stock.

Phibro Animal Health Trading Down 4.9%

Shares of PAHC opened at $34.37 on Friday. The firm’s 50-day moving average price is $51.85 and its 200-day moving average price is $46.27. The firm has a market capitalization of $1.39 billion, a price-to-earnings ratio of 14.75, a PEG ratio of 0.52 and a beta of 0.61. The company has a current ratio of 3.17, a quick ratio of 1.26 and a debt-to-equity ratio of 1.97. Phibro Animal Health Corporation has a 1-year low of $22.51 and a 1-year high of $60.08.

Phibro Animal Health (NASDAQ:PAHC) last announced its earnings results on Wednesday, May 6th. The company reported $0.76 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.04. The firm had revenue of $383.54 million for the quarter, compared to analyst estimates of $367.02 million. Phibro Animal Health had a net margin of 6.35% and a return on equity of 37.14%. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. Sell-side analysts anticipate that Phibro Animal Health Corporation will post 3.06 EPS for the current year.

Phibro Animal Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 24th. Stockholders of record on Wednesday, June 3rd will be paid a dividend of $0.12 per share. The ex-dividend date of this dividend is Wednesday, June 3rd. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.4%. Phibro Animal Health’s payout ratio is presently 20.60%.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on PAHC. Morgan Stanley set a $49.00 price target on shares of Phibro Animal Health in a report on Friday, February 6th. Weiss Ratings lowered shares of Phibro Animal Health from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 8th. Zacks Research raised shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 11th. Citigroup cut their price target on shares of Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating on the stock in a report on Thursday. Finally, Wall Street Zen lowered shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Phibro Animal Health currently has a consensus rating of “Hold” and an average price target of $38.80.

Phibro Animal Health Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.